We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406595

CAS#: 1227637-23-1

Description: Tegatrabetan, also known as Tegavivint and BC2059, is an orally bioavailable and potent β-catenin inhibitor. BC2059 potently induces apoptosis as a single agent and in combination with bortezomib in multiple myeloma. BC2059 induced apoptosis in 10/10 genetically heterogeneous human myeloma cell lines (HMCL) treated with dosages ranging from 50-500nM.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-06-05. Prices are subject to change without notice.

Tegatrabetan is not available.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406595
Name: Tegatrabetan
CAS#: 1227637-23-1
Chemical Formula: C28H36N4O6S2
Exact Mass: 588.20763
Molecular Weight: 588.74
Elemental Analysis: C, 57.12; H, 6.16; N, 9.52; O, 16.31; S, 10.89

Synonym: BC2059; BC-2059; BC 2059; tegavivint; Tegatrabetan,

IUPAC/Chemical Name: (9E,10E)-2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime


InChi Code: InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,33-34H,9-10,13-16H2,1-4H3/b29-27-,30-28+/t17-,18+,19-,20+

SMILES Code: O=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

BC2059 disrupts the WNT/beta-catenin pathway in human tumor cells. In cancer cells, BC2059 potently inhibits the WNT/beta catenin pathway as measured by modulation of clinically relevant target gene expression and a specific decrease in beta catenin protein levels. The mechanism of action for BC2059 is targeted degradation of beta catenin protein in cancer cells followed by reduced expression of beta-catenin-regulated genes that are known to promote and maintain the malignant phenotype. This results in cell cycle arrest and subsequent apoptosis.


1: Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C,  Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2014 Dec 8. doi: 10.1038/leu.2014.340. [Epub ahead of print] PubMed PMID: 25482131.